MedTrace Logo

Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention

NCT05241431 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2022-02-15

No results posted yet for this study

Summary

Randomized, double-blinded, placebo-controlled study in AS patients with subclinical or clinical heart failure undergoing treatment with TAVR.

Conditions

  • Aortic Stenosis
  • Left Ventricle Hypertrophied

Interventions

DRUG

SGLT2 inhibitor

10 mg orally once daily in addition to standard medical treatment.

DRUG

Placebo

Placebo tablets similar to active treatment.

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Steen Hvitfeldt Poulsen · Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-12
Primary Completion
2024-03-01
Completion
2024-04-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05241431 on ClinicalTrials.gov